Phathom Pharmaceuticals (PHAT) Earnings Date & Reports

Key Takeaways

• Phathom Pharmaceuticals reported third-quarter 2026 net revenue of $84.7 million, up 71% year over year and 14% sequentially.
• Non-GAAP earnings per share (EPS) came in at $0.04, while the GAAP net loss narrowed to $13.9 million (about $0.16 per share).
• The company delivered its second consecutive quarter of positive operating profit (excluding stock-based compensation) and positive cash from operations.
• Phathom reaffirmed full-year 2026 revenue guidance of $310 million to $325 million.
• Roughly 380,000 VOQUEZNA prescriptions were filled in Q3, pushing the cumulative total past 2 million filled prescriptions through mid-October.
• Gross margin landed near 78%, modestly below the roughly 80% target due to one-time charges.
• For more context on this ticker, explore Phathom Pharmaceuticals' Major News, Today's Price Move, Price Targets, and Forecast on Tickeron's dedicated pages.
• Explore Trending AI Robots to discover AI-driven trading ideas and market signals.

Earnings Context and Why It Matters

Phathom Pharmaceuticals' third-quarter results mark an important milestone in the company's transition from a cash-burning biotech launch story to a commercially self-sustaining gastrointestinal (GI) franchise. The quarter's 71% revenue growth, combined with a second straight period of operating profitability and positive operating cash flow, signals that the VOQUEZNA franchise is scaling toward durable profitability. For investors, this report matters because it tests whether management's GI-focused sales strategy and expense discipline can convert strong prescription demand into sustained bottom-line improvement. With full-year guidance reaffirmed, the results offer a clearer picture of the company's trajectory heading into 2027.

Reported Results

For the third quarter ended September 30, 2026, Phathom reported net revenue of $84.7 million, a 71% increase from $49.5 million a year earlier and a 14% sequential gain. Approximately 380,000 VOQUEZNA prescriptions were filled during the quarter, including about 248,000 covered prescriptions and roughly 132,000 cash-pay prescriptions.

On a GAAP basis, the net loss narrowed to $13.9 million, or $0.16 per share, compared with a $30.0 million loss in the prior-year quarter. On a non-GAAP basis, the company posted EPS of $0.04, reflecting the removal of non-cash items such as stock-based compensation and certain interest charges. Revenue came in slightly below some consensus estimates, while non-GAAP EPS modestly beat expectations.

Operating profit, excluding stock-based compensation, reached about $5.8 million, and cash generated from operations was roughly $2.1 million. Cash operating expenses totaled about $60.5 million. Gross margin was approximately 78%, below the company's roughly 80% guidance, primarily due to one-time charges in cost of revenues. Phathom ended the quarter with $184.6 million in cash and cash equivalents and reaffirmed full-year 2026 revenue guidance of $310 million to $325 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps surface trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening, making it a practical resource for both active traders and longer-term investors looking to refine their watchlists.

Market Reaction and Investor Sentiment

Investor reaction to Phathom's third-quarter results leaned positive, with shares trading higher in early activity following the announcement as the market focused on the company's revenue growth and sustained profitability milestone rather than the slight revenue miss versus consensus. The reaffirmed full-year revenue guidance and commentary pointing toward continued operating profitability into the fourth quarter provided a supportive backdrop for sentiment. However, the stock has faced broader pressure over the trailing twelve months, and investor attention remains divided between the encouraging commercial momentum and lingering questions about gross-margin consistency, one-time cost items, and the pace of the company's path to durable positive cash flow in 2027.

Forward Outlook and Key Factors to Monitor

Looking ahead, Phathom's reaffirmed full-year 2026 revenue guidance of $310 million to $325 million suggests a meaningful fourth-quarter step-up is required, making prescription trends and covered-volume growth a critical near-term metric to watch. Management expects the full-year gross-to-net discount to land toward the lower end of its 55%–59% range, which could support revenue recognition if channel mix remains favorable.

On the cost side, investors should monitor whether gross margin returns toward the roughly 80% target now that the third quarter's one-time charges are behind the company. Cash operating expenses, guided at $235 million to $245 million excluding stock-based compensation, are tracking toward the lower end of that range, reinforcing the path to profitability.

Key catalysts ahead include continued growth in covered prescriptions, the outcome of clinical programs such as the eosinophilic esophagitis (EoE) and as-needed studies, and the company's progress toward its stated goal of durable positive cash flow in 2027. Changes to cash covenant requirements beginning in late 2027 also bear monitoring, though Phathom's current cash balance remains comfortably above its near-term requirements.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations